Alegra

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alegra

What is Alegra? A Foundational Definition

The information presented here establishes the identity, classification, and high-level mechanism of the medicinal entity Fexofenadine Hydrochloride (commonly known by the trade name Allegra or Alegra), strictly excluding details on specific uses, dosage, and safety information.


Quick Facts: Fexofenadine Hydrochloride

Property Description
Active ingredient Fexofenadine Hydrochloride
Form Tablet, oral suspension
Pharmacological class Second-generation H₁-receptor antagonist
General purpose Mitigate allergic manifestations
Origin Synthetic chemical entity

What Type of Medicine is Allegra? (Classification and Origin)

Allegra is a medicine defined by its active component, Fexofenadine Hydrochloride, which is formally categorized as a second-generation H₁-receptor antagonist. It belongs to the group of antihistamines, synthetic substances designed to counteract the effects of histamine in the body. Fexofenadine Hydrochloride has a synthetic origin, being derived chemically as a piperidine derivative, and it is primarily provided as an Over-The-Counter (OTC) single-ingredient product in many global markets. This classification as a second-generation agent is characterized by its high selectivity for peripheral H₁ receptors, a key factor distinguishing it from older compounds.

Composition and Physical Forms

The product's essential composition consists of its active ingredient, Fexofenadine Hydrochloride, along with various inactive ingredients, or excipients, that give the medicine its physical structure. It is available for oral intake in multiple dosage forms, most commonly as a film-coated tablet, but also as an orally disintegrating tablet and an oral suspension. The availability of these distinct forms, especially the oral suspension, is designed to accommodate patient needs, such as the pediatric population who require a liquid formulation.

General Purpose and Mechanism Principle

The general purpose of this medicine is to broadly help relieve the manifestations of allergic reactions caused by the release of histamine within the body, such as the temporary discomfort often experienced during exposure to seasonal allergens. It achieves this by functioning as a selective peripheral H₁-blocker; this mechanism involves Fexofenadine Hydrochloride competing with histamine for binding sites on receptors located in tissues outside of the brain. The drug exhibits limited penetration of the blood-brain barrier, a characteristic that reduces common side effects like notable drowsiness.

Regulatory References

  1. Fexofenadine: MedlinePlus Drug Information
  2. FEXOFENADINE HYDROCHLORIDE tablet, film coated - DailyMed

What side effects are possible with Alegra?

Possible Side Effects and Safety Information

This section details the officially documented adverse reactions, frequency classifications, and safety considerations for Fexofenadine Hydrochloride, based strictly on government regulatory documents.

Adverse Reaction Scope

Classification Tier System-Organ Classes Involved Examples of Documented Effects
Common Nervous System Disorders, Gastrointestinal Disorders Headache, Somnolence (Drowsiness), Dizziness, Nausea
Uncommon / Frequency Not Known Psychiatric Disorders, Cardiac Disorders, Immune System Disorders Insomnia, Nervousness, Palpitations, Tachycardia, Fatigue

The most commonly documented adverse reactions, such as headache and somnolence, are categorized as Common based on regulatory frequency frameworks. The documented potential for drowsiness is generally lower compared to older antihistamine compounds.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions: The official label documents Hypersensitivity Reactions as a potential serious event, which may include manifestations such as Angioedema (swelling) and Urticaria (hives).

Safety Restrictions: The medicine is restricted for use in individuals with known hypersensitivity to Fexofenadine Hydrochloride or any of its excipients. Co-administration notes indicate that taking the medicine with certain fruit juices (apple, grapefruit, orange) or antacids containing aluminum or magnesium may reduce drug absorption, a factor related to systemic exposure.

Population-Specific Safety

Official safety information notes that clearance of Fexofenadine is reduced in patients with renal impairment (kidney problems). While no specific dose adjustment is universally mandated for elderly patients, the risk of toxic reactions may be greater in this group, as they are more likely to have age-related decreased renal function.

Regulatory Safety Summary: The official safety profile is established by classifying common effects and clearly separating them from rare, serious immune system-related events like Angioedema. This structured approach, along with specific warnings regarding renal impairment and absorption-related restrictions, defines the boundaries of the drug’s documented safety characteristics.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Fexofenadine Hydrochloride (Alegra) outlines specific clinical manifestations and mandated emergency actions in case of overdose.

Documented Overdose Presentation

Symptoms associated with an overdose, as documented in regulatory sources, are generally consistent with the known adverse effect profile. These include reports of drowsiness, dizziness, fatigue, and dry mouth. The regulatory classification confirms that taking more than the prescribed amount can cause serious health problems. Furthermore, the maximum tolerated dose of Fexofenadine Hydrochloride has not been formally established.

Emergency Actions and Management

In the event of a suspected or known overdose, official government guidance requires the user to seek medical help or to contact a Poison Control Center right away. This instruction is mandatory due to the potential for serious outcomes.

Medical management, as officially described in product information, focuses on symptomatic and supportive treatment. Standard measures are recommended to remove any unabsorbed medicinal product. It is officially stated that no specific antidote is known for Fexofenadine Hydrochloride overdose. Additionally, haemodialysis has been documented as being ineffective for removing the substance from the blood and is therefore not utilized in overdose management. No specific population-based adjustments to management are officially detailed in the core regulatory summaries.

Therapeutic Uses of Alegra

Main Uses and Benefits of Alegra

Alegra is a second-generation antihistamine primarily used to manage symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria. Unlike earlier antihistamines, it is designed to be non-sedating, allowing for the management of allergic conditions without significant impact on alertness.

Management of Allergic Rhinitis

Alegra is frequently utilized to alleviate the symptoms triggered by outdoor and indoor allergens, such as pollen, mold, dust mites, and pet dander. These symptoms typically include:

  • Sneezing: Reducing the frequency of sudden sneezing fits.
  • Rhinorrhea: Decreasing the production of excess nasal mucus (runny nose).
  • Itching: Relieving itchy sensations in the nose, throat, and roof of the mouth.
  • Ocular Symptoms: Managing itchy, red, or watery eyes associated with allergic reactions.

Treatment of Chronic Idiopathic Urticaria

In addition to respiratory allergies, Alegra is used to treat chronic idiopathic urticaria, a condition characterized by the recurrent appearance of hives without an identifiable cause. Its use in this context provides several benefits:

  • Reduction of Hives: Helping to decrease the number and size of raised, itchy wheals on the skin.
  • Relief from Pruritus: Significantly reducing the intense itching associated with chronic skin reactions.
  • Improvement in Quality of Life: By controlling skin discomfort and visible symptoms, it helps reduce the daily interference caused by chronic hives.

Mechanism of Action and Advantages

The primary benefit of Alegra lies in its ability to selectively block H1 receptors. By preventing histamine from binding to these receptors, the medication interrupts the inflammatory cascade that leads to allergy symptoms.

A key characteristic of this treatment is its limited ability to cross the blood-brain barrier. This property is what distinguishes it from first-generation antihistamines, as it provides relief from allergy symptoms with a significantly lower profile of drowsiness or cognitive impairment for most individuals.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Alegra

The use of Alegra (Fexofenadine Hydrochloride) is strictly defined by regulatory eligibility rules based on age, physiological status, and known contraindications. The official profile for this medicine identifies populations who are prohibited from use and those who require restricted use.

Contraindicated Populations The medicine is formally contraindicated for patients with known hypersensitivity or allergy to fexofenadine or any of its ingredients. Patients with Phenylketonuria (PKU) must not use the Orally Disintegrating Tablet (ODT) formulation due to the presence of phenylalanine.

Age and Organ Function Rules Eligibility for children varies by age and condition: the medicine is approved for Chronic Urticaria (hives) in infants 6 months of age and older, but use is not established for infants under six months. Children under two years are not approved for Seasonal Allergic Rhinitis.

Use is restricted for populations with altered drug clearance. Patients with decreased renal function require special professional consideration due to altered drug processing. Similarly, older adults (aged 65 and above) require consideration due to the higher likelihood of age-related kidney decline. Patients with hepatic impairment do not typically require a restriction.

Reproductive Status Use during pregnancy is restricted, and is only permitted if the potential benefit is deemed to justify the potential risk to the fetus. Use by nursing mothers is generally advised with caution.

What should I know about interactions with other medicines?

The official regulatory documents for Fexofenadine Hydrochloride (Alegra) establish the interaction profile based on effects that significantly alter the drug's systemic exposure. These interactions are fundamentally governed by drug transport mechanisms, rather than the hepatic CYP-450 enzyme system, which is documented to play a minimal role in the drug's clearance. No drug-drug combination is formally labeled as contraindicated in the official labeling.


Key Interaction Outcomes

Interacting Substance Formal Outcome Restriction/Rule
Ketoconazole & Erythromycin Officially increases Fexofenadine plasma exposure (C max and AUC). Studies show AUC increases up to 164% (Ketoconazole). No formal contraindication; use is permissible under standard conditions.
Aluminum/Magnesium Antacids Officially decreases Fexofenadine bioavailability due to physical binding in the gut. Mandatory separation: Must not be taken closely in time. Regulatory guidelines recommend an administration separation of at least 2 hours.
Fruit Juices (Apple, Orange, Grapefruit) Officially reduces Fexofenadine systemic exposure and bioavailability. Avoid co-ingestion: The medicine must be taken with water only.

Pharmacodynamic and Population Notes

Official regulatory studies have confirmed that Fexofenadine does not potentiate the effects of alcohol. This is a specific documented negation of a potential pharmacodynamic interaction. Furthermore, a specific pharmacokinetic note is maintained for certain patient populations: Fexofenadine clearance is decreased in individuals with severe renal impairment, a condition which officially results in significantly increased systemic exposure and AUC compared to healthy subjects.

Mechanism of Action

Fexofenadine, the active component in Alegra, functions as a selective peripheral H1 receptor antagonist. The molecular target is the histamine H1 receptor, a G-protein coupled receptor expressed on the surface of various cell types, including endothelial cells and cells in the respiratory and gastrointestinal tracts. Fexofenadine binds to and stabilizes the inactive conformation of the H1 receptor, thereby preventing the binding and subsequent activation by endogenous histamine.

This interaction blocks the typical intracellular cascade initiated by histamine binding, which normally involves G q protein coupling, phospholipase C activation, and subsequent inositol triphosphate ( IP3) and diacylglycerol ( DAG) signaling. By inhibiting H1 receptor-mediated signaling, fexofenadine prevents the histamine-induced increase in intracellular calcium concentration, which is a key step in downstream cellular processes. Additionally, the compound exhibits minimal penetration across the blood-brain barrier. The system-level consequence of this peripheral H1 receptor antagonism is the modulation of histamine-mediated physiological responses in targeted non-neuronal tissues.

Dosage and Administration Information

How Alegra (Fexofenadine) is Used

The usage of Fexofenadine Hydrochloride involves specific administration routes, dosage regimens, and contextual constraints. The medicine is intended for oral administration and is available in forms including film-coated tablets and oral suspension.


Standard Dosing Regimens and Frequency

Dosage is typically categorized by age group. For adults and children 12 years and older, standard use often involves a dose of 180 mg once daily or, in some regimens, 60 mg twice daily. Dosing for children aged 6 to 11 years is generally established at 30 mg twice daily. The scheduling aims to provide symptomatic relief for a 24-hour period per dose.


Administration Conditions

Proper use involves specific intake conditions. The medicine should be taken with water, and consumption with fruit juices (such as grapefruit, orange, or apple juice) should be avoided, as these may interfere with the absorption of the active ingredient. Additionally, an interval of at least 2 hours should be maintained between the administration of Fexofenadine and antacids containing aluminium or magnesium hydroxide. Tablets and Orally Disintegrating Tablets (ODTs) are intended to be swallowed or dissolved intact and should not be chewed.


Population-Specific Use

Dose adjustments are utilized for specific patient populations. For adults and children aged 12 years and older with renal impairment, the starting dose is often adjusted to 60 mg once daily. Children aged 6–11 years with renal impairment are generally advised to use 30 mg once daily. For patients with hepatic impairment or older adults, no dose adjustment is typically considered necessary.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase III Clinical Trial Findings

Research evaluated whether joint function and pain could be supported in adult participants with chronic inflammatory conditions. Trial data found changes in disease activity over 6 months in a cohort of 300 patients compared to a placebo group.

  • Primary Endpoint: Trial 301 investigated the impact on joint swelling and tenderness. Studies examined the combination with Therapy B in severe cases.
  • Secondary Endpoint: Research examined the relationship between use and inflammation markers, such as C-reactive protein (CRP).

Observational and Real-World Evidence

A collection of retrospective studies followed most patients over a period of 18 months. These observational studies included a broader patient population than the initial Phase III trials.

  • Specific Sub-Populations: Use in people with liver impairment was a consideration in some studies. Research evaluated the combined use of this medication with immunosuppressants.
  • Symptom Change: Evidence explored whether use related to a change in acute symptoms in patients with moderate-to-severe disease. Certain findings were reported in the patient subset whose use began at an earlier stage of disease.

Ongoing Research Areas

Ongoing research is focusing on the use in pediatric populations, though evidence remains limited. It is not yet clear whether the formulation impacts absorption rates, and studies continue to explore this area.

  • New Formulations: Studies are assessing whether a new slow-release capsule could be supported for a different administration schedule.
  • Biomarker Analysis: Researchers are exploring how genetic markers may relate to the individual change experienced by participants.

Frequently Asked Questions (FAQ)

Common questions about Alegra (FAQ)

Q: What is the main reason doctors prescribe Alegra?

According to the official product information, Fexofenadine (Alegra’s active ingredient) is officially indicated for the symptomatic treatment of seasonal allergic rhinitis (commonly known as hay fever) and chronic idiopathic urticaria (long-term hives).


Q: How quickly can I expect Alegra to start working?

Regulatory information describes Fexofenadine as having a rapid absorption. Studies and general information indicate that the drug typically begins its effect, or onset of action, within one to three hours after taking a dose.


Q: Is Alegra considered a 'non-drowsy' medicine?

Yes, Fexofenadine is generally classified as a non-drowsy, second-generation antihistamine. This classification is due to its limited ability to penetrate the blood-brain barrier, which is the technical reason it is associated with less sedation than older antihistamines.


Q: Can Alegra be taken with food, or does it matter?

Official guidance emphasizes taking the medicine with water and avoiding fruit juices, which can interfere with absorption. Some specific formulations, like orally disintegrating tablets (ODTs), may be recommended in regulatory documents to be taken on an empty stomach.


Q: Are there any common supplements that interact with Alegra?

Regulatory guidance advises caution, stating there is often not enough information to confirm the safety of complementary medicines, herbal remedies, and supplements when they are taken alongside Fexofenadine.


Q: Does Alegra interact with any common pain relievers like ibuprofen?

Official guidance indicates that taking Fexofenadine with common pain relievers such as paracetamol or ibuprofen is not typically associated with a known drug interaction.


Q: What are the most common side effects listed for Alegra?

Common side effects listed in regulatory information often include headache, a degree of sleepiness/drowsiness, tiredness/fatigue, nausea, and stomach upset or indigestion.


Q: Is it normal to feel a dry mouth or headache after taking Alegra?

Both headache and dry mouth are listed among the effects sometimes noted in the official side effect profiles for the drug, though dry mouth may be more common with specific combination products.


Q: Are there any serious side effects of Alegra that I should be aware of?

Regulatory information describes rare but serious effects, including signs of a severe allergic reaction, such as swelling of the face, throat, or tongue, and difficulty breathing.


Q: Are there known concerns about taking Alegra during pregnancy?

Fexofenadine use is often not recommended during pregnancy unless considered clearly necessary. This cautious stance is taken due to a lack of extensive, controlled human safety studies.


Q: What is the guidance on using Alegra while breastfeeding?

Fexofenadine use is often not recommended while breastfeeding. While only small amounts are shown to enter breast milk, information suggests that infants may need to be monitored for signs of unusual sleepiness or irritability.


Q: Can Alegra affect the results of an allergy skin test?

Official guidelines mention that taking the medication may affect the results of an allergy skin test. Regulatory documents suggest that stopping the medication a few days before having the test may be necessary.


Q: Does Alegra lose its effectiveness if I take it every day for a long time?

Official regulatory literature indicates that prolonged use of Fexofenadine typically does not cause tachyphylaxis, which is the technical term for a rapid decrease in drug effectiveness over time.


Q: Is Alegra a steroid?

No. Fexofenadine, the active ingredient, is classified as an antihistamine. It works by blocking histamine receptors, and it is not classified as a steroid or corticosteroid.


Q: What is the difference between prescription Alegra and the over-the-counter version?

In some regulatory regions, Fexofenadine is available in different strengths and formulations. Certain dosages may be available only by prescription, while other, typically lower, dosages are available over-the-counter (OTC).


Q: Is it true that Alegra can sometimes cause nervousness or difficulty sleeping?

Regulatory information notes that rare side effects can include feelings of nervousness, as well as sleeplessness or trouble sleeping.


Q: Has Alegra been studied in people with asthma?

Some official research noted in regulatory documents mentions Fexofenadine’s ability to inhibit antigen-induced bronchospasm in animal models. The current product indications, however, focus on allergic rhinitis and urticaria.


Q: What does the research say about Alegra for long-term use?

Studies and regulatory literature indicate that Fexofenadine can be used for prolonged periods without leading to a loss of effectiveness, known as tachyphylaxis.


Q: Are there certain heart conditions that make using Alegra complicated?

Official information notes the importance of disclosing a history of heart problems to a prescriber. Fexofenadine is generally regarded as less likely to affect cardiac function than older antihistamines.


Q: Does Alegra affect my ability to drive or operate machinery?

Fexofenadine is generally unlikely to affect your ability to drive or operate machinery. However, regulatory information indicates that users should be aware of their personal reaction (such as watching for sleepiness or dizziness) before driving or operating machinery.


Q: Can Alegra be used to help with hives or just seasonal allergies?

Official information confirms that Fexofenadine is approved for the treatment of both seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria, which is the technical term for hives.


Q: What is the role of the inactive ingredients in Alegra tablets?

Official product information primarily highlights the presence of specific inactive ingredients, such as phenylalanine in some orally disintegrating tablets (ODTs). This is specifically to inform users with conditions like Phenylketonuria (PKU).


Q: What is the research background of Alegra?

Fexofenadine is known as a second-generation antihistamine. It is also notable as the active metabolite of the previously used drug, terfenadine, which was withdrawn from the market.


Q: How is Alegra categorized by major health organizations?

Official documents and health organizations categorize Fexofenadine as a second-generation antihistamine and a selective peripheral H1 receptor antagonist.


Q: Does Alegra interact with common antidepressants or anxiety medications?

Regulatory guidance advises caution when taking Fexofenadine with any medicine that causes drowsiness. Official interaction databases list a number of specific antidepressants and anxiety medications as needing close monitoring.


Q: Is it described as necessary to take Alegra at the exact same time every day?

Regulatory guidance for certain formulations indicates the medication should be taken at around the same time(s) every day when following a dosing schedule. This helps to maintain consistent relief over a 24-hour period.


Q: What official warnings are attached to Alegra?

Official warnings attached to the drug include the risk of reduced effectiveness if taken with fruit juices or certain antacids. There is also a warning that patients with kidney disease require a dose adjustment.


Q: Do studies show Alegra is suitable for year-round allergy symptoms?

Fexofenadine is officially indicated for the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Hives, or chronic idiopathic urticaria, is often a year-round condition, suggesting suitability for extended use related to that indication.


Q: Are there any foods or drinks that should be avoided when taking Alegra?

Official guidelines strictly advise avoiding consumption with fruit juices—specifically grapefruit, orange, or apple juice. This is because these juices are known to interfere with the drug’s proper absorption.


Q: Why do some people say Alegra causes fatigue, even if it's considered non-drowsy?

Although the drug is classified as non-drowsy, official side effect listings for Fexofenadine do include tiredness and sleepiness/drowsiness as recognized common or less common effects.


Q: Is Alegra used to treat pet allergies?

The drug is officially indicated for the symptomatic treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Regulatory documents do not list pet allergies as a specific indication, though it treats the common symptoms associated with pet allergy.


Q: Can Alegra be given to infants?

Official information indicates Fexofenadine is not approved for use in infants under 6 months for chronic urticaria, or under 2 years for seasonal allergic rhinitis. Specific low dosing begins at these ages for certain indications.


Q: What are the contraindications listed for Alegra?

The primary contraindication (a reason not to use the drug) listed in official documents is a known hypersensitivity or allergic reaction to Fexofenadine or any of the other ingredients in the product.


Q: Does Alegra have known interactions with common herbal remedies?

Official guidance states there is not enough information to confirm that complementary medicines, herbal remedies, and supplements are safe to take with Fexofenadine.

How should Alegra be stored and disposed of?

How to Store and Dispose of Allegra (Fexofenadine Hydrochloride)

The storage and disposal of Allegra must strictly adhere to the conditions mandated by official regulatory labeling, focused on maintaining product quality and safety.

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F).
Protection Keep the product protected from excessive moisture and excess heat.
Container Store in the tightly closed, original container. Do not use if the safety seal is torn or missing.
Child Safety Must be stored out of the reach of children.

Disposal

Unused or expired Allegra should be discarded according to regulatory guidelines. It is not on the FDA's list of medicines recommended for flushing. Disposal should be carried out through a drug take-back program or by mixing the medicine with an undesirable substance (like dirt or coffee grounds) and sealing it before placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alegra found in:

A-Z Index: